ArticlePloS one2023

High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer.

Lisa Svartdal Normann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.